Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Treasury Shares (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Treasury Shares for 5 consecutive years, with $2.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Treasury Shares fell 7.84% year-over-year to $2.1 million, compared with a TTM value of $2.1 million through Dec 2025, down 7.84%, and an annual FY2025 reading of $2.1 million, up 3407.27% over the prior year.
  • Treasury Shares was $2.1 million for Q4 2025 at Kiniksa Pharmaceuticals International, down from $2.2 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $2.4 million in Q4 2023 and bottomed at $457566.0 in Q2 2025.
  • Average Treasury Shares over 5 years is $1.6 million, with a median of $1.8 million recorded in 2022.
  • The sharpest move saw Treasury Shares surged 148.75% in 2023, then crashed 80.35% in 2025.
  • Year by year, Treasury Shares stood at $885021.0 in 2021, then skyrocketed by 96.88% to $1.7 million in 2022, then surged by 37.56% to $2.4 million in 2023, then decreased by 6.1% to $2.3 million in 2024, then dropped by 7.84% to $2.1 million in 2025.
  • Business Quant data shows Treasury Shares for KNSA at $2.1 million in Q4 2025, $2.2 million in Q3 2025, and $457566.0 in Q2 2025.